{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:16:14Z","timestamp":1788844574385,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005746","name":"Universidad Nacional del Litoral","doi-asserted-by":"publisher","award":["50120150100095LI"],"award-info":[{"award-number":["50120150100095LI"]}],"id":[{"id":"10.13039\/501100005746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005746","name":"Universidad Nacional del Litoral","doi-asserted-by":"publisher","award":["CAI+D 2016"],"award-info":[{"award-number":["CAI+D 2016"]}],"id":[{"id":"10.13039\/501100005746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.talanta.2019.120619","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T22:39:25Z","timestamp":1575499165000},"page":"120619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["A review of bioanalytical methods for the therapeutic drug monitoring of \u03b2-lactam antibiotics in critically ill patients: Evaluation of the approaches used to develop and validate quality attributes"],"prefix":"10.1016","volume":"210","author":[{"given":"Y.S.","family":"Caro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"De Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2019.120619_bib1","series-title":"Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics","first-page":"1","article-title":"Overview of therapeutic drug monitoring","author":"Clarke","year":"2016"},{"key":"10.1016\/j.talanta.2019.120619_bib2","series-title":"Clinical Pharmacy Education, Practice and Research","first-page":"425","article-title":"Therapeutic drug monitoring","author":"Junaid","year":"2019"},{"key":"10.1016\/j.talanta.2019.120619_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CCM.0000000000002210","article-title":"Right dose, right now: customized drug dosing in the critically ill","volume":"45","author":"Roberts","year":"2017","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.talanta.2019.120619_bib4","series-title":"Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics","first-page":"3","article-title":"Introduction to Pharmacodynamics","author":"Craig","year":"2014"},{"key":"10.1016\/j.talanta.2019.120619_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","article-title":"Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of beta-lactam antibiotic concentration in human plasma","volume":"468","author":"Rigo-Bonnin","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2019.120619_bib6","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures","volume":"73","author":"Wong","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib7","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2016.08.015","article-title":"Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis","volume":"48","author":"Tsai","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijantimicag.2016.04.025","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection","volume":"48","author":"Kongthavonsakul","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/aas.12808","article-title":"Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients","volume":"60","author":"Petersson","year":"2016","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.talanta.2019.120619_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10156-011-0271-9","article-title":"Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis","volume":"17","author":"Ohata","year":"2011","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2011.04.019","article-title":"Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia","volume":"38","author":"Jaruratanasirikul","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib13","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc10257","article-title":"Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy","volume":"15","author":"Seyler","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dkt304","article-title":"Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic\/pharmacodynamic analysis","volume":"69","author":"Asin-Prieto","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.10741011","article-title":"Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT","volume":"7","author":"Bauer","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2019.120619_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/phar.1604","article-title":"Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy","volume":"35","author":"Awissi","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.talanta.2019.120619_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijantimicag.2014.09.009","article-title":"Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration","volume":"45","author":"Jamal","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2215\/CJN.10260915","article-title":"Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin-tazobactam in critically ill patients undergoing CRRT","volume":"11","author":"Shotwell","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.talanta.2019.120619_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","article-title":"Impact of beta-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy","volume":"49","author":"Economou","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib20","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/cc13886","article-title":"\u03b2-lactam antibiotic concentrations during continuous renal replacement therapy","volume":"18","author":"Beumier","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jiac.2017.09.005","article-title":"Dosing optimization of meropenem based on a pharmacokinetic analysis in patients receiving hemodiafiltration and an in vitro model","volume":"24","author":"Yokoyama","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijantimicag.2012.05.010","article-title":"Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring","volume":"40","author":"Troger","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jiac.2015.02.011","article-title":"Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis","volume":"21","author":"Kawano","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcrc.2018.08.026","article-title":"Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion","volume":"48","author":"Carrie","year":"2018","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jac\/dky434","article-title":"Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models","volume":"74","author":"Dhaese","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","article-title":"Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.talanta.2019.120619_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijantimicag.2010.01.022","article-title":"Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?","volume":"35","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib30","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01582-09","article-title":"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration","volume":"54","author":"Bilgrami","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000321488","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"30","author":"Choi","year":"2010","journal-title":"Blood Purif."},{"key":"10.1016\/j.talanta.2019.120619_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00548-10","article-title":"Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis","volume":"55","author":"Connor","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.talanta.2019.120619_bib35","first-page":"1","article-title":"Does beta-lactam pharmacokinetic variability in critically III patients justify therapeutic drug monitoring? A systematic Review","volume":"35","author":"Sime","year":"2012","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.talanta.2019.120619_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/cc13945","article-title":"Beta-lactam antibiotic dosing during continuous renal replacement therapy: how can we optimize therapy?","volume":"18","author":"De Waele","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.talanta.2019.120619_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2016.10.018","article-title":"Might real-time pharmacokinetic\/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?","volume":"49","author":"Pea","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/clinchem\/44.2.375","article-title":"Analytical goals in therapeutic drug monitoring","volume":"44","author":"Bowers","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.talanta.2019.120619_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chroma.2015.03.059","article-title":"Towards a full integration of optimization and validation phases: an analytical-quality-by-design approach","volume":"1395","author":"Hubert","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2019.120619_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpba.2018.07.050","article-title":"Risk-based approach for method development in pharmaceutical quality control context: a critical review","volume":"161","author":"Deidda","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.aca.2009.06.015","article-title":"Experimental design in chemistry: a tutorial","volume":"652","author":"Leardi","year":"2009","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2019.120619_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.talanta.2014.01.034","article-title":"Experimental design and multiple response optimization. Using the desirability function in analytical methods development","volume":"124","author":"Candioti","year":"2014","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2019.120619_bib43","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jpba.2017.05.006","article-title":"An overview of experimental designs in HPLC method development and validation","volume":"147","author":"Sahu","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib44","series-title":"International Conference on Harmonization","article-title":"Pharmaceutical development Q8(R2)","year":"2009"},{"key":"10.1016\/j.talanta.2019.120619_bib45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijantimicag.2015.06.016","article-title":"Assays for therapeutic drug monitoring of beta-lactam antibiotics: a structured review","volume":"46","author":"Carlier","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.clinbiochem.2009.12.007","article-title":"Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin","volume":"43","author":"Delattre","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.talanta.2019.120619_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpba.2014.08.005","article-title":"Simple and suitable immunosensor for beta-lactam antibiotics analysis in real matrixes: milk, serum, urine","volume":"106","author":"Merola","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib48","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4067\/S0034-98872015000800013","article-title":"Monitorizaci\u00f3n terap\u00e9utica de antibi\u00f3ticos: nuevas metodolog\u00edas: biosensores","volume":"143","author":"Soto","year":"2015","journal-title":"Rev. Med. Chile"},{"key":"10.1016\/j.talanta.2019.120619_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1469-0691.12074","article-title":"Fast determination of antibiotics in whole blood","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.talanta.2019.120619_bib50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.microc.2018.12.018","article-title":"Innovative ultra-sensitive spectrofluorimetric method for nanogram detection of doripenem monohydrate in human plasma, urine and pharmaceutical formulation","volume":"145","author":"Salman","year":"2019","journal-title":"Microchem. J."},{"key":"10.1016\/j.talanta.2019.120619_bib51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mimet.2016.07.020","article-title":"A microbiological method for determining serum levels of broad spectrum beta-lactam antibiotics in critically ill patients","volume":"129","author":"Fridlund","year":"2016","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.talanta.2019.120619_bib52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpba.2018.01.031","article-title":"Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS\/MS method","volume":"152","author":"Paal","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2017.02.012","article-title":"Ceftriaxone pharmacokinetics by new simple and sensitive ultra-high-performance liquid chromatography method","volume":"88","author":"Campos","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.talanta.2019.120619_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpba.2017.05.037","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics - influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV","volume":"143","author":"Pinder","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchromb.2017.01.016","article-title":"Quantification of meropenem in human plasma by HILIC - tandem mass spectrometry","volume":"1046","author":"Martens-Lobenhoffer","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchromb.2017.09.014","article-title":"A simple ultra-high-performance liquid chromatography-high resolution mass spectrometry assay for the simultaneous quantification of 15 antibiotics in plasma","volume":"1065\u20131066","author":"Lefeuvre","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib57","first-page":"4","article-title":"Desarrollo y validaci\u00f3n de un procedimiento de medida para la medici\u00f3n simult\u00e1nea de la concentraci\u00f3n de masa de ceftazidima, meropenem y piperacilina en el plasma mediante UHPLC-MS\/MS","volume":"10","author":"Rigo Bonnin","year":"2017","journal-title":"Rev. del Lab. Clin."},{"key":"10.1016\/j.talanta.2019.120619_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jpba.2017.03.035","article-title":"Meropenem, levofloxacin and linezolid in human plasma of critical care patients: a fast semi-automated micro-extraction by packed sorbent UHPLC-PDA method for their simultaneous determination","volume":"140","author":"Ferrone","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib59","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jchromb.2017.06.014","article-title":"Simultaneous determination of nine beta-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography-tandem mass spectrometry","volume":"1060","author":"Abdulla","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib60","first-page":"31","article-title":"Determination of meropenem levels in human serum by high-performance liquid chromatography with ultraviolet detection","author":"Roth","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.talanta.2019.120619_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpba.2016.08.010","article-title":"A simple and rapid RP-HPLC method for the simultaneous determination of piperacillin and tazobactam in human plasma","volume":"131","author":"Veillette","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchromb.2014.11.034","article-title":"Ultrafast quantification of beta-lactam antibiotics in human plasma using UPLC-MS\/MS","volume":"978\u2013979","author":"Carlier","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jpba.2011.12.018","article-title":"Development of an UPLC-MS\/MS method for the determination of antibiotic ertapenem on dried blood spots","volume":"61","author":"la Marca","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.plabm.2015.03.003","article-title":"Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood","volume":"1","author":"Crutchfield","year":"2015","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/j.talanta.2019.120619_bib65","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jchromb.2010.05.027","article-title":"Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection","volume":"878","author":"McWhinney","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib66","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jchromb.2011.03.001","article-title":"Simultaneous determination of eight beta-lactam antibiotics in human serum by liquid chromatography-tandem mass spectrometry","volume":"879","author":"Ohmori","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jchromb.2012.09.016","article-title":"A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection","volume":"907","author":"Briscoe","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib68","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpba.2019.01.039","article-title":"A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM","volume":"169","author":"Zou","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpba.2013.11.004","article-title":"Simultaneous analysis of antibiotics in biological samples by ultra high performance liquid chromatography-tandem mass spectrometry","volume":"89","author":"Cazorla-Reyes","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jchromb.2014.04.029","article-title":"Simultaneous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies","volume":"960","author":"Sime","year":"2014","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpba.2018.09.044","article-title":"Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV","volume":"163","author":"Kratzer","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib72","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jchromb.2009.12.025","article-title":"Liquid chromatography\/electrospray tandem mass spectrometry method for the determination of cefuroxime in human plasma: application to a pharmacokinetic study","volume":"878","author":"Partani","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib73","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpba.2009.12.010","article-title":"High-throughput determination of faropenem in human plasma and urine by on-line solid-phase extraction coupled to high-performance liquid chromatography with UV detection and its application to the pharmacokinetic study","volume":"52","author":"Xie","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpha.2013.02.003","article-title":"Simultaneous pharmacokinetic assessment of cefadroxil and clavulanic acid in human plasma by LC-MS and its application to bioequivalence studies","volume":"3","author":"Nagarajan","year":"2013","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib75","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijantimicag.2012.06.022","article-title":"Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS\/MS method","volume":"40","author":"Carlier","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2019.120619_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cca.2018.03.021","article-title":"Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens","volume":"482","author":"Verhoven","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2019.120619_bib77","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jchromb.2011.03.038","article-title":"A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study","volume":"879","author":"Dailly","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.talanta.2012.10.024","article-title":"Rapid quantification of six beta-lactams to optimize dosage regimens in severely septic patients","volume":"103","author":"Wolff","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2019.120619_bib79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4236\/ijamsc.2014.22005","article-title":"A liquid chromatography assay for the simultaneous quantification of piperacillin and ciprofloxacin in human plasma and dialysate in critically ill patients Undergoing Continuous Renal Replacement Therapy","volume":"2","author":"Scheer","year":"2014","journal-title":"Int. J. Anal. Mass Spectrom. Chromatogr."},{"key":"10.1016\/j.talanta.2019.120619_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.talanta.2012.10.046","article-title":"Development and validation of a fast and uniform approach to quantify beta-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry","volume":"103","author":"Colin","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2019.120619_bib81","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1128\/AAC.00951-13","article-title":"Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clinbiochem.2014.08.002","article-title":"Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma","volume":"47","author":"Casals","year":"2014","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.talanta.2019.120619_bib83","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/2193-1801-2-575","article-title":"LC\/UV determination of cefradine, cefuroxime, and cefotaxime in dairy milk, human serum and wastewater samples","volume":"2","author":"Qureshi","year":"2013","journal-title":"SpringerPlus"},{"key":"10.1016\/j.talanta.2019.120619_bib84","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1128\/AAC.00533-11","article-title":"Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring","volume":"55","author":"Verdier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2019.120619_bib85","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.jchromb.2011.09.031","article-title":"Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants","volume":"879","author":"Cohen-Wolkowiez","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2019.120619_bib86","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2013.12.002","article-title":"Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients","volume":"90","author":"Miranda Bastos","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2019.120619_bib87","doi-asserted-by":"crossref","first-page":"e4243","DOI":"10.1002\/bmc.4243","article-title":"A microscale HPLC-UV method for the determination of latamoxef in plasma: an adapted method for therapeutic drug monitoring in neonates","volume":"32","author":"Dong","year":"2018","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.talanta.2019.120619_bib88","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1128\/AAC.00025-14","article-title":"Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method","volume":"58","author":"van Rijn","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914019312524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914019312524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:52:00Z","timestamp":1778658720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914019312524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":88,"alternative-id":["S0039914019312524"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2019.120619","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of bioanalytical methods for the therapeutic drug monitoring of \u03b2-lactam antibiotics in critically ill patients: Evaluation of the approaches used to develop and validate quality attributes","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2019.120619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120619"}}